Evidence map›Paper›PMID 21474571›Full record

ArticleChest2011

The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study.

Victor Kim, MeiLan K Han, Gwendolyn B Vance, Barry J Make, John D Newell, John E Hokanson, Craig P Hersh, Douglas Stinson, Edwin K Silverman, Gerard J Criner and 1 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chest, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00608764 (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 174 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 5 pooled it
20.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00608764 active not recruitingnot on this map

Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene)

TypeobservationalSponsorBrigham and Women's HospitalRan2007 to 2028Enrolled10,718ConditionsPulmonary Disease, Chronic Obstructive, Emphysema, Bronchitis, Chronic
3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 5 syntheses or guidelines pooled it, 324 citations in OpenAlex.

  1. Impact of N-Acetylcysteine on Mucus Hypersecretion in the Airways: A Systematic Review.International journal of chronic obstructive pulmonary disease · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Trial
  7. Trial
  8. Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.American journal of respiratory and critical care medicine · 2017
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Victor KimTemple University School of Medicine, Philadelphia, PA. Electronic address: victor.kim@tuhs.temple.edu.
MeiLan K HanUniversity of Michigan School of Medicine, Ann Arbor, MI.
Gwendolyn B VanceTemple University School of Medicine, Philadelphia, PA.
Barry J MakeNational Jewish Health, Denver, CO.
John D NewellNational Jewish Health, Denver, CO.
John E HokansonUniversity of Colorado at Denver, Denver, CO.
Craig P HershBrigham and Women's Hospital, Boston, MA.
Douglas StinsonNational Jewish Health, Denver, CO.
Edwin K SilvermanBrigham and Women's Hospital, Boston, MA.
Gerard J CrinerTemple University School of Medicine, Philadelphia, PA.
COPDGene Investigators
Temple University · USUniversity of Colorado Denver · USBrigham and Women's Hospital · USNational Jewish Health · USUniversity of Michigan–Ann Arbor · US

Funding

Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Genetic Epidemiology of COPDU01HL089856 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SILVERMAN, EDWIN K · 2007 to 2021
$20.7M
Th17 inflammation is responsible for mucous metaplasia in COPDK23HL094696 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI KIM, VICTOR · 2011 to 2014
$563k
TOPOLOGY AND FUNCTION IN RED CELL AE1 (BAND 3) PROTEINF32HL008989 · NHLBI · EMORY UNIVERSITY · PI TIMMER, RICHARD T · 1993 to 1995
–
Medical Research Council G0701127NCATS NIH HHS UL1 TR000454NHLBI NIH HHS F32 HL008989NHLBI NIH HHS K23 HL094696NHLBI NIH HHS U01 HL089856NHLBI NIH HHS U01 HL08989
6 · The paper itself

Abstract

backgroundChronic bronchitis (CB) in patients with COPD is associated with an accelerated lung function decline and an increased risk of respiratory infections. Despite its clinical significance, the chronic bronchitic phenotype in COPD remains poorly defined.

methodsWe analyzed data from subjects enrolled in the Genetic Epidemiology of COPD (COPDGene) Study. A total of 1,061 subjects with GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage II to IV were divided into two groups: CB (CB+) if subjects noted chronic cough and phlegm production for ≥ 3 mo/y for 2 consecutive years, and no CB (CB-) if they did not.

resultsThere were 290 and 771 subjects in the CB+ and CB- groups, respectively. Despite similar lung function, the CB+ group was younger (62.8 ± 8.4 vs 64.6 ± 8.4 years, P = .002), smoked more (57 ± 30 vs 52 ± 25 pack-years, P = .006), and had more current smokers (48% vs 27%, P < .0001). A greater percentage of the CB+ group reported nasal and ocular symptoms, wheezing, and nocturnal awakenings secondary to cough and dyspnea. History of exacerbations was higher in the CB+ group (1.21 ± 1.62 vs 0.63 ± 1.12 per patient, P < .027), and more patients in the CB+ group reported a history of severe exacerbations (26.6% vs 20.0%, P = .024). There was no difference in percent emphysema or percent gas trapping, but the CB+ group had a higher mean percent segmental airway wall area (63.2% ± 2.9% vs 62.6% ± 3.1%, P = .013).

conclusionsCB in patients with COPD is associated with worse respiratory symptoms and higher risk of exacerbations. This group may need more directed therapy targeting chronic mucus production and smoking cessation not only to improve symptoms but also to reduce risk, improve quality of life, and improve outcomes. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00608764; URL: www.clinicaltrials.gov.

Indexed as

AgedBronchitis, ChronicComorbidityCross-Sectional StudiesDisease ProgressionFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMultivariate AnalysisPhenotypeQuality of LifeRespiratory Function TestsSmokingSmoking Cessation

Identifiers

PMID21474571
PMCPMC3168856
OpenAlexW2146514656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.